Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study)

NCT03323710 is registered in ClinicalTrials.gov with Military Institute od Medicine National Research Institute as lead sponsor.

NCT NCT03323710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03323710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study)
Lead sponsor
Military Institute od Medicine National Research Institute
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2018
Completion date
December 31, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma